Bank of New York Mellon Corp Purchases 13,109 Shares of Calyxt Inc (NASDAQ:CLXT)

Share on StockTwits

Bank of New York Mellon Corp lifted its position in Calyxt Inc (NASDAQ:CLXT) by 60.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 34,973 shares of the company’s stock after purchasing an additional 13,109 shares during the period. Bank of New York Mellon Corp owned about 0.11% of Calyxt worth $436,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Calyxt by 56.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 21,848 shares of the company’s stock worth $273,000 after purchasing an additional 7,887 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Calyxt by 52.3% in the second quarter. Wells Fargo & Company MN now owns 24,679 shares of the company’s stock valued at $309,000 after acquiring an additional 8,475 shares in the last quarter. Gilder Gagnon Howe & Co. LLC bought a new stake in Calyxt in the first quarter valued at $172,000. FMR LLC boosted its holdings in Calyxt by 0.4% in the first quarter. FMR LLC now owns 4,903,294 shares of the company’s stock valued at $86,249,000 after acquiring an additional 17,440 shares in the last quarter. Finally, Swiss National Bank bought a new stake in Calyxt in the second quarter valued at $228,000. Hedge funds and other institutional investors own 28.05% of the company’s stock.

Several analysts recently weighed in on CLXT shares. BidaskClub upgraded shares of Calyxt from a “strong sell” rating to a “sell” rating in a report on Thursday, September 12th. National Securities reiterated a “buy” rating and issued a $28.00 price target (down previously from $35.00) on shares of Calyxt in a report on Thursday, August 8th. Finally, Zacks Investment Research cut shares of Calyxt from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $20.00.

NASDAQ:CLXT opened at $4.19 on Tuesday. The stock has a market cap of $137.71 million, a P/E ratio of -4.60 and a beta of 2.47. The firm’s fifty day simple moving average is $5.99 and its 200 day simple moving average is $11.09. Calyxt Inc has a twelve month low of $4.03 and a twelve month high of $19.30. The company has a quick ratio of 15.94, a current ratio of 15.96 and a debt-to-equity ratio of 0.23.

Calyxt (NASDAQ:CLXT) last announced its earnings results on Tuesday, August 6th. The company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.03. Calyxt had a negative net margin of 5,509.93% and a negative return on equity of 36.21%. The firm had revenue of $0.41 million for the quarter, compared to analysts’ expectations of $0.30 million. On average, analysts expect that Calyxt Inc will post -1.11 EPS for the current fiscal year.

Calyxt Company Profile

Calyxt, Inc, a consumer-centric food- and agriculture-focused company, develops healthier specialty food ingredients and food crops using gene-editing technology for agriculture in the United States. It engages in the development of high oleic and low linolenic soybean product candidates; high fiber wheat; improved quality alfalfa product candidates; and cold storable and reduced browning potatoes.

Featured Article: Growth Stocks, What They Are, What They Are Not

Want to see what other hedge funds are holding CLXT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calyxt Inc (NASDAQ:CLXT).

Institutional Ownership by Quarter for Calyxt (NASDAQ:CLXT)

Receive News & Ratings for Calyxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.